Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Hughes, G. R. V.

doi:10.1136/bmj.287.6399.1088

Cited by 874 publications

(369 citation statements)

References 10 publications

Supporting

Mentioning

344

Contrasting

Unclassified

Order By: Relevance

“…Lupus anticoagulant may increase the risk of thrombosis superimposed on preexisting retinal vasculitis, and thus increase the incidence of clinically obvious ischemic lesions (26). The previously noted association between cerebral disease and lupus anticoagulant, as well as cerebral disease and retinopathy, may partly account for this finding (27).…”

Section: Discussionmentioning

confidence: 98%

Lupus retinopathy

Stafford-Brady

Urowitz

Gladman

et al. 1988

Arthritis & Rheumatism

183

View full text Add to dashboard Cite

In a prospective study of 550 patients with systemic lupus erythematosus (SLE), 41 were found to have retinopathy. Lupus retinopathy in the majority of cases consisted of a microangiopathy, with an excellent prognosis for vision. Five patients developed other complications that resulted in loss of visual acuity. Lupus retinopathy was associated with active SLE in 88% of patients and with lupus cerebritis in 73% of cases. Retinopathy in SLE was a marker of poor prognosis for survival.

show abstract

Section: Discussionmentioning

confidence: 98%

Lupus retinopathy

Stafford-Brady

Urowitz

Gladman

et al. 1988

Arthritis & Rheumatism

183

View full text Add to dashboard Cite

show abstract

“…The antiphospholipid syndrome (APS) is an acquired multisystem disorder characterized by hypercoagulation in which thrombosis and recurrent fetal loss develop 4 . The serological markers for this syndrome are antiphospholipid antibodies (aPLs), such as the lupus anticoagulant (LA), anti-cardiolipin antibody (aCL) 5,6 , antibody against anticardiolipin β 2 -glycoprotein I complex antibody (CL/β 2 GPI), and anti-phosphatidylserine-prothrombin complex antibody (aPS/PT) 7,8 .…”

Section: Introductionmentioning

confidence: 99%

Antiphospholipid antibodies in patients with autoimmune blistering disease

Echigo

Hasegawa

Inaoki

et al. 2007

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Objective: To determine the serum levels and frequency of antiphospholipid antibodies (aPLs) and confirm the clinical importance of this antibodies in patients with autoimmune blistering disease (ABD). Methods:IgG and IgM anti-cardiolipin antibodies (aCL), IgG anti-cardiolipin-β 2 glycoprotein I complex antibody (aCL/β 2 GPI), and IgG anti-phosphatidylserine-prothrombin complex antibody (aPS/PT) were examined with an enzyme-linked immunosorbent assay in 71 patients with ABD, including pemphigus vulgaris, pemphigus foliaceous, and bullous pemphigoid. Results:The prevalence of IgG aCL, IgM aCL, aCL/β 2 GPI, and IgG aPS/PT were positive for 22.4%, 9.1%, 9.9%, and 25.4% of the ABD patients, respectively, while they were not detected in any of the normal controls. Ten of 20 (50%) patients with ABD who were attending our hospital in 2004 were positive for aPLs, and thromboembolism was detected in 7/10 (70%) patients with aPLs.

show abstract

“…22 Histological findings in APS neurophathy include distinctive microangiopathic features (focal and diffuse) that might affect any of the vessels within the intrarenal vasculature, including the glomeruli (Figure 3). 1,15,16 In studies of kidney biopsy samples from patients with primary APS, Nochy and co-workers18 showed that all vaso-occlusive lesions were characterized by acute thrombosis (TMA) and chronic vascular lesions, such as fibrous intimal hyperplasia of interlobular arteries, recanalizing thrombi in arteries and arterioles, fibrous occlusions and focal cortical atrophy.18 Ultrastructural findings might include glomerular basement membrane reduplication associated with glomerular basement membrane wrinkling.15,16 Fakhouri and co-workers23 found evidence of glomerulonephritis in 29 biopsy samples obtained from patients with primary APS without. 23 Characteristic features of APS nephropathy were observed in 20 (69%) of specimens.…”

Section: Aps Nephropathymentioning

confidence: 99%

Renal involvement in antiphospholipid syndrome

et al. 2014

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an autoimmune disease defined by the presence of arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive for antiphospholipid antibodies (aPL). APS can be isolated (known as primary APS) or associated with other autoimmune diseases, such as systemic lupus erythematosus (SLE; known as secondary APS). The kidney is a major target organ in APS and renal thrombosis can occur at any level within the vasculature of the kidney (renal arteries, intrarenal arteries, glomerular capillaries and renal veins);events reflect the site and size of the involved vessels. Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions, without glomerular or arterial immune deposits on immunofluorescence. Renal prognosis is affected by the presence of aPL in patients with lupus nephritis and can be poor. In patients with SLE and aPL, biopsy should be performed because inflammatory and thrombotic lesions require different therapeutic approaches. Renal involvement in patients with definite APS is treated by anticoagulation with long-term warfarin. The range of renal manifestations associated with APS is broadening and, therefore, aPL has increasing relevance in end-stage renal disease, transplantation and pregnancy.

show abstract

Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Cited by 874 publications

References 10 publications

Lupus retinopathy

Lupus retinopathy

Antiphospholipid antibodies in patients with autoimmune blistering disease

Renal involvement in antiphospholipid syndrome

Contact Info

Product

Resources

About